• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

FDA clears C. Light to market retinal eye movement monitor, Retitrack™

Article

This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.

Photo courtesy of C. Light Technologies, Inc.

Photo courtesy of C. Light Technologies, Inc.

The U.S. Food and Drug Administration (FDA) cleared the Retitrack by C. Light Technologies, Inc., for marketing through premarket notification 510(k). The Retitrack device will provide a new tool to better understand oculomotor function via the retina, providing concrete and objective metrics to medical professionals.

The Retitrack is a monocular, tabletop eye movement monitor that is intended for recording, viewing, measuring, and analyzing temporal characteristics of fixation and saccadic responses when viewing a visual stimulus and is intended for use by healthcare practitioners within the healthcare setting (e.g., physician's office, clinic, laboratory).

Photo courtesy of C. Light Technologies, Inc.

Photo courtesy of C. Light Technologies, Inc.

The Retitrack

The Retitrack stands alone as the first retinal eye-movement monitor cleared for use within the healthcare field. The device operates by recording 10-second, high-resolution retinal videos at the photoreceptor level, allowing for quantification of eye motion down to 0.1 degrees. Its accompanying software extracts and analyzes both fixation (microsaccades and drift) and saccadic eye movements in real time and generates a comprehensive summary report for clinical interpretation.

"Fixational eye movements have previously eluded clinical quantification, posing a significant challenge to healthcare professionals who are aiming to improve prognostic care. With our novel technology, we've unlocked the potential of one of the smallest motor movements in the human body, offering invaluable data that will drive the future of clinical care," said Christy Sheehy-Bensinger, PhD, CEO and co-founder.

"We are gratified that our device is cleared for marketing and that we hit our seed funding milestone. Our device and its accompanying software will revolutionize healthcare by empowering clinicians with significant new insights into an individual's oculomotor function, as opposed to existing devices reporting on retinal structure alone," Sheehy-Bensinger continued.

"C. Light fills a critical need in research and the clinic. We're very excited by how quickly this team has achieved their major milestones. C. Light will have a significant, lasting impact on the field in coming years," said lead investor James Wang, Creative Ventures.

"I am proud of our team. We meticulously operate at a high standard to propel our tech development forward and ensure our product is scientifically well-conceptualized and anchored in precision and accuracy," said Joe Xing, PhD, CTO and co-founder.

Related Videos
Raman Bhakhri, OD, FAAO, overviews his talk on medications' potential side effects on the retina with Optometry Times
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
© 2024 MJH Life Sciences

All rights reserved.